Hongbo Yang
Boston
Education
Ph.D., biology, and M.S., statistics, University of Illinois at Urbana-Champaign; B.S., biology, Nankai University, PRC
Summary of Experience
Dr. Yang specializes in health economics and outcomes research (HEOR). She has extensive experience in developing HEOR strategies and evaluating the clinical and economic impacts of a broad range of diseases and treatments. Dr. Yang has conducted and directed numerous studies in a variety of therapeutic areas, including autoimmune diseases, infectious diseases, diabetes, blood disorders, oncology, women’s health, and central nervous system diseases. Her work has included systematic literature reviews, gap analyses, economic modeling, and evaluations of treatment efficacy, health care resource use, direct and indirect costs, and patient-reported outcomes. Dr. Yang has led evidence submissions to health technology assessment agencies in the UK, France, Germany, Canada, Australia, and Japan. Her work has been published in many peer-reviewed journals and featured at various conferences.
Selected Publishing
-
Indirect Treatment Comparison (Itc) of the Efficacy of Vutrisiran and Tafamidis for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Expert Opinion on Pharmacotherapy, 2023
2023Merkel M, Danese D, Chen C, Wang J, Wu A, Yang H, Lin H
-
Healthcare Resource Use and Reimbursement Amount by Site of Care in Patients with Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell (CAR-T) Therapy - a Retrospective Cohort Study Using CMS 100% Medicare Claims Database
Leukemia & Lymphoma, 2023
2023Yang H, Bollu V, Lim S, Tesfaye M, Dalal AA, Lax A, Sethi S, Zhao J
-
Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States
Journal of International Medical Research, 2022
2022Kraus SR, Li J, Kristy RM, Lockefeer A, Yang H, Zhou M, Walker DR
-
Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial
Leukemia & Lymphoma, 2022
2022Zeidan AM, Qi CZ, Yang H, Garnham A, Shah MV, Pandya BJ
-
Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease
Advances in Therapy, 2022
2022Setyawan J, Mu F, Zichlin ML, Billmyer E, Downes N, Yang H, Azimi N, Strand V, Yarur A
-
The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases
Advances in Therapy, 2022
2022Setyawan J, Billmyer E, Mu F, Yarur A, Zichlin ML, Yang H, Downes N, Azimi N, Strand V
-
Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison
Leukemia & Lymphoma, 2022
2022Schuster SJ, Zhang J, Yang H, Agarwal A, Tang W, Martinez-Prieto M, Bollu V, Kuzan D, Maziarz RT, Kersten MJ
-
Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials
Dermatologic Therapy, 2022
2022Lebwohl MG, Soliman AM, Yang H, Wang J, Hagan K, Padilla B, Pinter A
-
Indirect Comparison of Tisagenlecleucel and Historical Treatments for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Blood Advances, 2022
2022Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam C, Salles G
-
Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States
Leukemia & Lymphoma, 2022
2022Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, Lee S, Dalal A, Bollu V
-
Health care resource utilization and cost burden of hemophilia B in the United States
Blood Advances, 2021
2021Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, Sawyer EK, Li N
-
Evaluating the use of pharmacological stress agents during single-photon emission computed tomography myocardial perfusion imaging tests after inadequate exercise stress test
Journal of Nuclear Cardiology, 2021
2021Yang H, Faust E, Gao E, Sethi S, Kitt TM, Kristy RM, Spalding JR, Xu Y
-
Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes
European Journal of Haematology, 2021
2021 -
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
Value in Health, 2021
2021Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M
-
Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study
Frontiers in Medicine, 2021
2021Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, Wang Y, Xu C, Hongbo Yang H, Moritz ML
-
Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan
Transplantation and Cellular Therapy, 2021
2021Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A
-
Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan
Transplantation and Cellular Therapy, 2021
2021Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A
-
Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
Blood Advances, 2021
2021Verneris MR, Ma Q, Zhang J, Keating A, Tiwari R, Li J, Yang H, Agarwal A, Pacaud L
-
Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated Diseases
Clinical Therapeutics, 2021
2021Setyawan J, Mu F, Yarur A, Zichlin ML, Yang H, Fernan C, Billmyer E, Downes N, Azimi N, Strand V
-
-
Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia
Journal of Managed Care & Specialty Pharmacy, 2021
2021Pandya BJ, Qi CZ, Garnham A, Yang H, Shah MV, Zeidan AM
-
Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis
Journal of Dermatological Treatment, 2021
2021Lebwohl M, Soliman AM, Yang H, Wang J, Freimark J, Puig L
-
The Development of Health Technology Assessment in Asia: Current Status and Future Trends
Value in Health Regional Issues, Volume 21, May 2020
2020 -
A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Advances in Therapy, 2020
2020Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E
-
Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective
Journal of Managed Care & Specialty Pharmacy, 2020
2020 -
Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective
Journal of Medical Economics, 2020
2020 -
An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan
Journal of Dermatological Treatment, 2020
2020Saeki H, Ishii K, Joshi A, Bensimon AG, Yang H, Kawaguchi I
-
A Longitudinal Assessment of the Impact of Endometriosis on Patients' Salary Growth and Risk of Leaving the Workforce
Advances in Therapy, 2020
2020Estes SJ, Soliman AM, Yang H, Wang J, Freimark J
-
Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
Drug Safety, 2020
2020Schultz NM, Penson DF, Wilson S, Song Y, Yang H, Ramaswamy K, Lowentritt B
-
Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population
JBMR Plus, 2020
2020Kilpatrick RD, Chiuve SE, Leslie WD, Wegrzyn LR, Gao W, Yang H, Soliman AM, Snabes MC, Koenigsberg S, Zhong J, Xiang C, Watts NB
-
A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 mut+ acute myeloid leukemia in a US health plan
Journal of Medical Economics, 2020
2020Pandya BJ, Yang H, Schmeichel C, Qi CZ, Shah MV
-
Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
Journal of Managed Care & Specialty Pharmacy, 2019
2019Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, Lowentritt B
-
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America
Advances in Therapy, 2019
2019Muniz DQ, Ratto B, Yang H, Zhao J, Jenkins M, Signorovitch J, Dezzani L, Salman P, Medina ML, Lopera D, Lerzo G, Del Castillo C, Chacon M, Martin A, Campos-Gomez S
-
Factors that impact a patient's experience when undergoing single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in the US: A survey of patients, imaging center staff, and physicians
Journal of Nuclear Cardiology, 2019
2019Li J, Walker DR, Biesbrock G, Kristy RM, Yang H, Gao E, Koenigsberg S, Spalding JR, Kitt TM
-
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer
Current Oncology, 2019
2019Levy BP, J E Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M
-
Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers
Orphanet Journal of Rare Diseases, 2019
2019Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, Yang H
-
Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis
Diabetes Therapy. Mar 29 2018.
2018 -
Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and Income
British Journal of Dermatology, 2018
2018Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J
-
Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis
Advances in Therapy. 2018 Oct;35(10):1639-1655
2018Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V
-
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
2018 Oct;35(10):1564-1577
2018Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL
-
Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mutated and Wild Type Acute Myeloid Leukemia: A Medical Chart Study
European Journal of Haematology. December 22, 2018
2018 -
A Risk Score for Fluconazole Failure among Patients with Candidemia
Antimicrobial Agents Chemotherapy. 2017 Apr 24;61(5). pii: e02091-16. doi: 10.1128/AAC.02091-16. Print 2017 May.
2017Yang H, Ostrosky-Zeichner L, Harrington R, Azie N, Li N, Zhao J, Koo V, Wu EQ
-
Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
Advances in Therapy; 2017 Jan;34(1):207-220. doi: 10.1007/s12325-016-0443-1. Epub 2016 Dec 2.
2017Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J.
-
Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis
Journal of Medical Economics, 2017 October
2017 -
Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests
Journal of Medical Economics. Aug 2017;20(8):777-785
2017Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ
-
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant pr
Journal of Medical Economics. Feb 2017;20(2):121-128
2017Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S
-
Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy
Journal of Women's Health. Jun 2017;26(6):644-654
2017 -
Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons
Clinical Therapeutics. Apr 2017;39(4):849-862 e846
2017Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, Mittal M, Lebwohl M
-
Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors
American Health and Drug Benefits. November 2017;10(8):408-415
2017Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB
-
Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive A(1)
Advances in Therapy. Jan 2017;34(1):207-220
2017Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J
-
Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims Analysis
Advances in Therapy. Nov 2017;34(11):2436-2451
2017Surrey ES, Soliman AM, Yang H, Du EX, Su B
-
Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment (1)
Journal of Medical Economics. Oct 2017;20(10):1056-1065
2017 -
Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study
Diabetes Therapy. Jun 2017;8(3):555-571
2017Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R
-
Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients
Antimicrobial Agents and Chemotherapy, 2016 06; 60(6): 3398-3406. e-pub ahead of print 2016/03/24
2016Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J.
-
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant pr
Journal of Medical Economics, 2016 09: 1-8
2016Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.
-
Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study
BMC Infectious Diseases, December 1, 2016
2016Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR
-
Brentuximab Vedotin Compared with Other Therapies in Relapsed/Refractory Hodgkin Lymphoma Post ASCT: Median Overall Survival Meta-Analysis
Curr Med Res Opin. 2015 May 7:1-48
2015Bonthapally V, Yang H, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D
-
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data
Curr Med Res Opin. 2015 May; 31(5):993-1001
2015Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D.
-
The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013
Am J Obstet Gynecol. 2015 Mar 11
2015Soliman AM, Yang H, Du EX, Kelkar SS, Winkel C
-
The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas
Curr Med Res Opin. 2015 Mar; 31(3):537-45
2015Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V.
-
Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases
Fertil Steril. 2015 Jan; 103(1):163-71
2015 -
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe
J Med Econ. 2014 Dec; 17(12):837-45
2014Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H.
-
Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States
Appl Health Econ Health Policy. 2014 Feb; 12(1):85-93
2014 -
Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec
Can J Psychiatry. 2014 Nov; 59(11):597-608
2014Lachaine J, De G, Sikirica V, Van Stralen J, Hodgkins P, Yang H, Heroux J, Ben Amor L.
-
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review
Curr Med Res Opin. 2014 Apr; 30(4):537-45
2014Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.
-
-
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity
J Med Econ. 2012; 15(6):1078-87
2012Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ
-
Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients
J Med Econ. 2012; 15(4):786-95
2012Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.
-
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer
Journal of Medical Economics, 1-26, November 16, 2012
2012 -
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-
Br J Dermatol. 2012 Dec; 167(6):1374-81
2012Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM
-
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs
Postgrad Med. 2012 Jan; 124(1):124-32
2012 -
Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer
J Med Econ. 2011; 14(5):542-52
2011 -
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis
J Med Econ. 2011; 14(3):315-23
2011 -
Domains of heterochromatin protein 1 required for Drosophila melanogaster heterochromatin spreading
Genetics. 2009 Aug;182(4):967-77. doi: 10.1534/genetics.109.105338. Epub 2009 Jun 1
2009Hines KA, Cryderman DE, Flannery KM, Yang H, Vitalini MW, Hazelrigg T, Mizzen CA, Wallrath LL
-
The multiple facets of histone H4-lysine 20 methylation
Biochemistry and Cell Biology; 2009 Feb;87(1):151-61. doi: 10.1139/O08-131
2009Yang H, Mizzen CA
-
Certain and progressive methylation of histone H4 at lysine 20 during the cell cycle
Molecular and Cellular Biology, 2008 Jan;28(1):468-86. Epub 2007 Oct 29
2008Pesavento JJ, Yang H, Kelleher NL, Mizzen CA
-
Preferential dimethylation of histone H4 lysine 20 by Suv4-20
The Journal of Biological Chemistry; 2008 May 2;283(18):12085-92. doi: 10.1074/jbc.M707974200. Epub 2008 Feb 21
2008Yang H, Pesavento JJ, Starnes TW, Cryderman DE, Wallrath LL, Kelleher NL, Mizzen CA
-
Proliferation and apoptosis of smooth muscle cells in benign prostate hyperplasia
Chinese Journal of Pathophysiology; 2005, 21: 817-819
2005Shi J, Li J, Yang H, Wang K, Wu Q, Zhang J.
-
Association lifetimes of hydrophobic amino acid pairs measured directly from molecular dynamics simulations
Journal of the American Chemical Society, 2003 Nov 19;125(46):13968-9
2003Yang H, Elcock AH
News
-
December 10, 2021
-
October 15, 2021
-
June 4, 2021
